Accumulating evidence suggests that adaptations of carbohydrate and creatine metabolism, as well as other HIF-1α -independent mechanisms, may enable cancers to survive hypoxic conditions despite anti-HIF1α therapy [47]. This evidence concerns the gene HIF1A and cancer.